ArticleFrontiers in bioengineering and biotechnology2020
An Inflamed Human Alveolar Model for Testing the Efficiency of Anti-inflammatory Drugs
Article in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- A Barrier to Defend - Models of Pulmonary Barrier to Study Acute Inflammatory Diseases.Frontiers in immunology · 2022Pooled it
- FN-silk membrane enables alveologenesis processes and self-organization of the H441 epithelial cell line into native-like alveolar morphology.Scientific reports · 2026Article
- Alignment of in vitro and in vivo pulmonary inflammation models using crystalline quartz silica.Particle and fibre toxicology · 2026Article
- MiR-483-5p has the potential to serve as a biomarker in perioperative respiratory adverse events in children under general anesthesia.BMC pediatrics · 2026Article
- A stretchable human lung-on-chip model of alveolar inflammation for evaluating anti-inflammatory drug response.Bioengineering & translational medicine · 2025Article
- Gene regulation and signaling pathways in immune response to respiratory sensitizers: a database analysis.Frontiers in immunology · 2025Article
- The transcriptomic signature of respiratory sensitizers using an alveolar model.Cell biology and toxicology · 2024Article
- HumanTissue barriers · 2024Review
- An In Vitro Alveolar Model Allows for the Rapid Assessment of Particles for Respiratory Sensitization Potential.International journal of molecular sciences · 2023Article
- Glucocorticoid therapy in respiratory illness: bench to bedside.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2022Review
- Methodological Approaches To Assess Innate Immunity and Innate Memory in Marine Invertebrates and Humans.Frontiers in toxicology · 2022Review
- A High-Throughput Distal Lung Air-Blood Barrier Model Enabled By Density-Driven Underside Epithelium Seeding.Advanced healthcare materials · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A large number of prevalent lung diseases is associated with tissue inflammation. Clinically, corticosteroid therapies are applied systemically or via inhalation for the treatment of lung inflammation, and a number of novel therapies are being developed that require preclinical testing. In alveoli, macrophages and dendritic cells play a key role in initiating and diminishing pro-inflammatory reactions and, in particular, macrophage plasticity (M1 and M2 phenotypes shifts) has been reported to play a significant role in these reactions. Thus far, no studies with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.